ADRX insider filings
ADARx Pharmaceuticals, Inc. — 24 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2026-09-30. Screen ADRX transaction legs live →
Insider transaction summary — last 90 days
2026-07-10 to 2026-10-08, from the filings listed below: 24 insider filings (Forms 3/4/5). Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 13 legs across 5 filings by 9 insiders — 5,161,516 shares, $87,745,772 total (shares × price as filed).
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 81.
- Largest priced transaction: purchase of 592,593 shares @ $17.00 ($10,074,081) by SR ONE CAPITAL MANAGEMENT, LLC, filed 2026-09-29.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| George Simeon — Director, 10% owner | 2 | 3 legs · 1,600,000 sh · $27,200,000 | — | 12 |
| SR ONE CAPITAL MANAGEMENT, LLC — 10% owner | 2 | 3 legs · 1,600,000 sh · $27,200,000 | — | 12 |
| GORDON CARL L — Director, 10% owner | 2 | 3 legs · 950,000 sh · $16,150,000 | — | 16 |
| ORBIMED ADVISORS LLC — Director, 10% owner & OrbiMed Capital GP VII LLC — Director, 10% owner & OrbiMed Israel GP II, L.P. — Director, 10% owner & OrbiMed Advisors Israel II Ltd — Director, 10% owner & OrbiMed Genesis GP LLC — Director, 10% owner | 1 | 3 legs · 950,000 sh · $16,150,000 | — | 16 |
| Chimovits Erez — Director | 2 | 1 leg · 61,516 sh · $1,045,772 | — | 8 |
| LAV Biosciences Fund V, L.P. — 10% owner & LAV Fund VI Opportunities, L.P. — 10% owner & LAV Fund VI, L.P. — 10% owner | 2 | — | — | 12 |
| Ackles Robert William — Chief People Officer | 2 | — | — | 1 |
| Fisk Ryan — CFO and CBO | 2 | — | — | 1 |
| Li Zhen — President and CEO, Director, 10% owner | 2 | — | — | 1 |
| MacLeod Alan Robert — Chief Scientific Officer | 2 | — | — | 1 |
+4 more insiders in the window, not shown — every filing appears in the table below.
Recent insider filings — ADARx Pharmaceuticals, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-30 | 4 | Chimovits Erez — Director | Conversion (C): 7,127,019 · Conversion (C): 1,333,975 · Conversion (C): 513,067 · Conversion (C): 256,448 · Purchase (P): 61,516 @ $17 · Conversion (C): 7,127,019 (derivative) @ $0 · +3 more | EDGAR |
| 2026-09-30 | 4 | GORDON CARL L — Director, 10% owner | Conversion (C): 10,690,530 · Conversion (C): 2,000,962 · Conversion (C): 769,601 · Conversion (C): 564,187 · Purchase (P): 300,249 @ $17 · Conversion (C): 7,127,019 · +13 more | EDGAR |
| 2026-09-30 | 4 | ORBIMED ADVISORS LLC — Director, 10% owner OrbiMed Capital GP VII LLC — Director, 10% owner OrbiMed Israel GP II, L.P. — Director, 10% owner OrbiMed Advisors Israel II Ltd — Director, 10% owner OrbiMed Genesis GP LLC — Director, 10% owner | Conversion (C): 10,690,530 · Conversion (C): 2,000,962 · Conversion (C): 769,601 · Conversion (C): 564,187 · Purchase (P): 300,249 @ $17 · Conversion (C): 7,127,019 · +13 more | EDGAR |
| 2026-09-29 | 4 | SR ONE CAPITAL MANAGEMENT, LLC — 10% owner | Conversion (C): 3,334,938 · Conversion (C): 1,113,666 · Conversion (C): 512,897 · Purchase (P): 592,593 @ $17 · Conversion (C): 1,538,691 · Purchase (P): 414,814 @ $17 · +9 more | EDGAR |
| 2026-09-29 | 4 | George Simeon — Director, 10% owner | Conversion (C): 3,334,938 · Conversion (C): 1,113,666 · Conversion (C): 512,897 · Purchase (P): 592,593 @ $17 · Conversion (C): 1,538,691 · Purchase (P): 414,814 @ $17 · +9 more | EDGAR |
| 2026-09-29 | 4 | LAV Biosciences Fund V, L.P. — 10% owner LAV Fund VI Opportunities, L.P. — 10% owner LAV Fund VI, L.P. — 10% owner | Conversion (C): 8,908,775 · Conversion (C): 1,667,469 · Conversion (C): 513,067 · Conversion (C): 153,868 · Conversion (C): 307,738 · Conversion (C): 307,738 · +6 more | EDGAR |
| 2026-09-28 | 4 | MacLeod Alan Robert — Chief Scientific Officer | Grant/award (A): 170,692 (derivative) @ $0 | EDGAR |
| 2026-09-28 | 4 | Zhu Rui (NMN) — Chief Technology Officer | Grant/award (A): 512,076 (derivative) @ $0 | EDGAR |
| 2026-09-28 | 4 | Ackles Robert William — Chief People Officer | Grant/award (A): 85,346 (derivative) @ $0 | EDGAR |
| 2026-09-28 | 4 | Fisk Ryan — CFO and CBO | Grant/award (A): 170,692 (derivative) @ $0 | EDGAR |
| 2026-09-28 | 4 | Li Zhen — President and CEO, Director, 10% owner | Grant/award (A): 1,024,152 (derivative) @ $0 | EDGAR |
| 2026-09-24 | 3 | SR ONE CAPITAL MANAGEMENT, LLC — 10% owner | Holdings only — no transactions reported | EDGAR |
| 2026-09-24 | 3 | ORBIMED ADVISORS LLC — Director, 10% owner OrbiMed Capital GP VII LLC — Director, 10% owner OrbiMed Israel GP II, L.P. — Director, 10% owner OrbiMed Advisors Israel II Ltd — Director, 10% owner | Holdings only — no transactions reported | EDGAR |
| 2026-09-24 | 3 | George Simeon — Director, 10% owner | Holdings only — no transactions reported | EDGAR |
| 2026-09-24 | 3 | Zhu Rui (NMN) — Chief Technology Officer | Holdings only — no transactions reported | EDGAR |
| 2026-09-24 | 3 | Li Zhen — President and CEO, Director, 10% owner | Holdings only — no transactions reported | EDGAR |
| 2026-09-24 | 3 | GORDON CARL L — Director, 10% owner | Holdings only — no transactions reported | EDGAR |
| 2026-09-24 | 3 | Fisk Ryan — CFO and CBO | Holdings only — no transactions reported | EDGAR |
| 2026-09-24 | 3 | MacLeod Alan Robert — Chief Scientific Officer | Holdings only — no transactions reported | EDGAR |
| 2026-09-24 | 3 | Chimovits Erez — Director | Holdings only — no transactions reported | EDGAR |
| 2026-09-24 | 3 | Ackles Robert William — Chief People Officer | Holdings only — no transactions reported | EDGAR |
| 2026-09-24 | 3 | TAGLIAFERRI MARY — Director | Holdings only — no transactions reported | EDGAR |
| 2026-09-24 | 3 | Huang Ying — Director | Holdings only — no transactions reported | EDGAR |
| 2026-09-24 | 3 | LAV Biosciences Fund V, L.P. — 10% owner LAV Fund VI Opportunities, L.P. — 10% owner LAV Fund VI, L.P. — 10% owner | Holdings only — no transactions reported | EDGAR |
Recent 8-K events — ADARx Pharmaceuticals, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-09-28 | 8-K | 3.02 — Unregistered Sales of Equity Securities 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
Registration filings — ADARx Pharmaceuticals, Inc.
Securities Act registration lifecycles tracked for this issuer (live-forward since 2026-08-01), threaded by SEC file number.
- SEC file 333-298782 (S-1) — latest: Final prospectus (424B4), filed 2026-09-28
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=ADRX returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →